Loading..

Amarin Corporation plc (AMRN) Report Analysis

Corporate Events

Positive

Sarissa Capital Management LP Provides Informat...

2022-06-16 10:11:00

On June 16, 2022, Sarissa Capital Management LP announced that it has discussed with the Company its intention to add directors to the Company...

Positive

Amarin Corporation plc Receives Positive CHMP O...

2022-06-10 10:00:00

marin Corporation plc announced that in response to Amarin’s Marketing Authorisation Application submission, the Committee for Medicinal Produ...

Negative

Amarin Corporation plc Announces Executive Changes

2022-06-06 20:36:00

Amarin Corporation plc announced that on June 1, 2022, Michael W. Kalb, company's Senior Vice President notified the company that he would be ...

Negative

Amarin Corporation plc Announces Management Changes

2022-06-06 12:15:00

Amarin Corporation plc announced the appointment of Tom Reilly as Chief Financial Officer, effective June 20, 2022. The appointment follows th...

Positive

Sarissa Capital Management LP Engages with Amar...

2022-06-03 09:18:00

On June 3, 2022, Sarissa Capital Management LP announced that it has engaged with Amarin Corporation plc and discussed about the Company’s fin...

Neutral

Amarin Corporation plc, Annual General Meeting,...

2022-05-24 21:17:00

Amarin Corporation plc, Annual General Meeting, Jun 27, 2022, at 14:00 Coordinated Universal Time. Location: Dublin offices of Arthur Cox LLP,...

Negative

Amarin Announces Appointment of New Directors a...

2022-05-19 12:23:00

Amarin Corporation plc announced a series of appointments and leadership changes to its Board of Directors, including: Appointment of Erin Enr...

Neutral

Amarin Corporation plc Presents at H.C. Wainwri...

2022-05-12 12:00:00

Amarin Corporation plc Presents at H.C. Wainwright Global Investment Conference 2022, May-25-2022 12:00 PM. Venue: Fontainebleau Miami Beach H...

Neutral

Amarin Corporation plc Presents at 2022 Jefferi...

2022-05-12 12:00:00

Amarin Corporation plc Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 01:00 PM. Venue: Marriott Marquis, New York City, ...

Neutral

Amarin Corporation plc Suspends Revenue Guidanc...

2022-05-04 11:00:00

Amarin Corporation plc suspended revenue guidance for the full year 2022. Given the ongoing global impact of COVID-19, as well as the uncertai...

Positive

Amarin Corporation plc Announces Results from I...

2022-05-03 12:00:00

Amarin Corporation plc announced the publication in the Journal of the American College of Cardiology (JACC) of a new REDUCE-IT® data analysis...

Neutral

Amarin Corporation plc to Report Q1, 2022 Resul...

2022-04-19 11:30:00

Amarin Corporation plc announced that they will report Q1, 2022 results at 8:00 AM, Eastern Daylight on May 04, 2022

Neutral

Amarin Corporation plc, Q1 2022 Earnings Call, ...

2022-04-19 11:30:00

Amarin Corporation plc, Q1 2022 Earnings Call, May 04, 2022

Neutral

Amarin Corporation plc Presents at American Col...

2022-03-21 12:30:00

Amarin Corporation plc Presents at American College of Cardiology Annual Scientific Session & Expo, Apr-02-2022 . Venue: Washington, District ...

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Glo...

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami B...

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Neutral

American College of Cardiology, Inc., American ...

2022-01-26 12:00:00

American College of Cardiology, Inc., American College of Cardiology Annual Scientific Session & Expo, Apr 01, 2022 through Apr 04, 2022. Venu...

Negative

Levi & Korsinsky, LLP Announces Commencement of...

2021-11-24 20:50:00

Levi & Korsinsky, LLP announced that all persons or entities who purchased or otherwise acquired securities of Amarin Corporation Plc between ...

Neutral

Amarin Corporation plc Presents at Piper Sandle...

2021-11-22 15:06:00

Amarin Corporation plc Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Positive

Amarin Reports Overview of Latest Clinical Rese...

2021-11-16 12:00:00

Amarin Corporation plc reported an overview of new data relating to VASCEPA®/VAZKEPA (icosapent ethyl) presented at the American Heart Associa...

Neutral

Amarin Corporation plc Presents at 12th Annual ...

2021-11-11 12:00:00

Amarin Corporation plc Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-16-2021 08:40 AM. Venue: London, United Kingdom. Sp...

Neutral

Amarin Corporation plc Presents at Piper Sandle...

2021-11-11 12:00:00

Amarin Corporation plc Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 . Speakers: Karim Mikha...

Positive

Amarin Corporation plc Announces Latest Researc...

2021-11-08 12:00:00

Amarin Corporation plc announced that new data that add to the growing body of knowledge on VASCEPA®/VAZKEPA (icosapent ethyl), including in p...

Neutral

Piper Sandler Companies, Piper Sandler 33rd Ann...

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Negative

The Schall Law Firm and Roche Freedman LLP File...

2021-10-24 13:00:00

The Schall Law Firm and Roche Freedman LLP announced that they have filed a class action lawsuit in the United States District Court for the D...

Neutral

Amarin Corporation plc, Q3 2021 Earnings Call, ...

2021-10-20 11:05:00

Amarin Corporation plc, Q3 2021 Earnings Call, Nov 03, 2021

Neutral

Amarin Corporation plc to Report Q3, 2021 Resul...

2021-10-20 11:05:00

Amarin Corporation plc announced that they will report Q3, 2021 results on Nov 03, 2021

Positive

Amarin Outlines New Go-To-Market Strategy to Ac...

2021-09-27 12:31:00

Amarin Corporation plc outlined its new Go-to-Market strategy to accelerate growth of VASCEPA® (icosapent ethyl) in the United States, which f...

Positive

Amarin Announces First European Launch of VAZKE...

2021-09-13 11:00:00

Amarin Corporation plc announced the first European launch of VAZKEPA (icosapent ethyl) in Germany. VAZKEPA received marketing authorization f...

Neutral

Amarin Corporation plc Presents at Cantor Globa...

2021-09-13 10:00:00

Amarin Corporation plc Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 02:40 PM. Venue: New York, United States.

Neutral

Amarin Corporation plc Presents at H.C. Wainwri...

2021-09-13 10:00:00

Amarin Corporation plc Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palac...

Positive

Amarin Reports Overview of Clinical Research Ev...

2021-08-31 11:00:00

Amarin Corporation plc reported an overview of new data relating to VASCEPA®/VAZKEPA (icosapent ethyl) presented at ESC Congress 2021, organiz...

Positive

Amarin Reports Data from Reduce-It® Showing Vas...

2021-08-23 07:15:00

Amarin Corporation plc announced that data adding to the growing body of knowledge on VASCEPA®/VAZKEPA (icosapent ethyl) in patients with prio...

Positive

Amarin Corporation plc Announces Latest Clinica...

2021-08-16 11:00:00

Amarin Corporation plc announced that new data that add to the growing body of knowledge on VASCEPA®/VAZKEPA (icosapent ethyl) in patients at ...

Neutral

Amarin Corporation plc to Report Q2, 2021 Resul...

2021-07-15 10:35:00

Amarin Corporation plc announced that they will report Q2, 2021 results on Aug 05, 2021

Neutral

Amarin Corporation plc, Q2 2021 Earnings Call, ...

2021-07-15 10:35:00

Amarin Corporation plc, Q2 2021 Earnings Call, Aug 05, 2021

Positive

Sarissa Capital Management LP Provides Information to Shareholders of Amarin Corporation plc

2022-06-16 10:11:00

On June 16, 2022, Sarissa Capital Management LP announced that it has discussed with the Company its intention to add directors to the Company board. In addition, Sarissa Capital Management LP stated that it intends to vote abstain on all matters at the annual meeting.

Positive

Amarin Corporation plc Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction

2022-06-10 10:00:00

marin Corporation plc announced that in response to Amarin’s Marketing Authorisation Application submission, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending that a marketing authorisation be granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA®. The CHMP recommendation is now expected to be reviewed by the European Commission, which has the authority to approve medicines for marketing in the European Union. A decision by the European Commission is expected to take place within 67 days of the CHMP opinion. The CHMP opinion is based on over a decade of development and testing of icosapent ethyl, including data from the REDUCE-IT® cardiovascular outcomes study. REDUCE-IT evaluated more than 8,000 high risk patients who despite having their cholesterol levels well controlled by statin therapy remained at significant risk of heart attack, stroke, or other major adverse cardiovascular events (MACE), including death. As published, patients in the REDUCE-IT study had a median follow-up period of nearly five years. Results from this study, in which all patients remained treated by statins (and by other contemporary therapies) and where half the patients received icosapent ethyl and the other half received placebo, demonstrated a 25% relative risk reduction (p<0.001) in the first occurrence of MACE in the intent-to-treat patient population with use of icosapent ethyl (4 grams daily) compared with placebo. Based on communications with the EMA they expect the indication language to be generally consistent with the following: That marketing authorisation be granted to icosapent ethyl to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (=150 mg/dL), and established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor. Ten years of market protection is expected to be granted in the European Union as part of a European Commission approval of the pending application. In addition, pending patent applications related to the REDUCE-IT study have the potential to extend exclusivity in Europe into 2039.

Negative

Amarin Corporation plc Announces Executive Changes

2022-06-06 20:36:00

Amarin Corporation plc announced that on June 1, 2022, Michael W. Kalb, company's Senior Vice President notified the company that he would be resigning from the company, and on June 6, 2022, Amarin announced the appointment of Tom Reilly as company's new Senior Vice President as successor to Mr. Kalb, effective June 20, 2022 (or such earlier date as may be agreed with the Company, the “ CFO Appointment Date”). Mr. Kalb is leaving the company to pursue other interests after transitioning the role to Mr. Reilly. Mr. Reilly, age 50, has more than 20 years of experience in building and leading finance and administration teams at life sciences companies both in the United States and globally. Most recently Mr. Reilly served as chief financial officer for Cara Therapeutics Inc. (“ Cara”), where he was responsible for leading all aspects of the Cara’s financial operations and planning. Prior to Cara, Mr. Reilly served as head of finance of the Allergan General Medicines business. Prior to joining Allergan, Mr. Reilly spent 14 years with Novartis where he served in roles of increasing responsibility, including finance head for Novartis’ Oncology Development unit, as chief financial officer for Novartis Pharma Austria and financial controller for Novartis USA’s Pharmaceutical Division. He earned his bachelor’s degree in finance from Manhattan College, an M.B. A in accounting from Seton Hall University and is a certified public accountant.

Negative

Amarin Corporation plc Announces Management Changes

2022-06-06 12:15:00

Amarin Corporation plc announced the appointment of Tom Reilly as Chief Financial Officer, effective June 20, 2022. The appointment follows the resignation of Michael W. Kalb who will leave the Company to pursue other interests after a brief transition period. Tom Reilly is an experienced senior leader with significant expertise in corporate and commercial finance in the pharmaceutical and biotechnology sectors. Most recently, he served as Chief Financial Officer for Cara Therapeutics, where he was responsible for leading all aspects of Cara's financial operations and planning. Prior to his role at Cara, Mr. Reilly served as Head of Finance for the U.S. General Medicines unit at Allergan, where he led all financial management for that business. Prior to Allergan, Mr. Reilly spent 14 years with Novartis where he served in roles of increasing responsibility, including Finance Head for the Novartis Oncology Development unit, CFO for Novartis Pharma Austria, Financial Controller for Novartis USA's Pharmaceutical Division as well as a series of roles supporting Novartis' financial planning and analysis and accounting. Earlier in his career, Mr. Reilly served in financial planning and finance roles at Pharmacia.Mr. Reilly holds a Bachelor of Science in Finance from Manhattan College and a Master of Business Administration in Accounting from Seton Hall University. About Amarin Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management.

Positive

Sarissa Capital Management LP Engages with Amarin Corporation plc

2022-06-03 09:18:00

On June 3, 2022, Sarissa Capital Management LP announced that it has engaged with Amarin Corporation plc and discussed about the Company’s financials. In addition, Sarissa Capital Management LP stated that it intends to seek representation on the Company’s board of directors.

Neutral

Amarin Corporation plc, Annual General Meeting, Jun 27, 2022

2022-05-24 21:17:00

Amarin Corporation plc, Annual General Meeting, Jun 27, 2022, at 14:00 Coordinated Universal Time. Location: Dublin offices of Arthur Cox LLP, Ten Earlsfort Terrace, Dublin 2 Ireland Agenda: To consider and to re-elect Mr. Karim Mikhail as a director; to re-elect Mr. Per Wold-Olsen as a director; to re-elect Ms. Erin Enright as a director; to re-elect Mr. Alfonso Zulueta as a director; to hold an advisory (non-binding) vote to approve the compensation of the Company’s “named executive officers”; and to discuss other matters.

Negative

Amarin Announces Appointment of New Directors and Board Leadership Changes

2022-05-19 12:23:00

Amarin Corporation plc announced a series of appointments and leadership changes to its Board of Directors, including: Appointment of Erin Enright and Alfonso “Chito” Zulueta to the Board, effective immediately. Ms. Enright and Mr. Zulueta will stand for re-election to the Board at the Company’s 2022 Annual Meeting in June. Per Wold-Olsen, a director since January 2022, has been named Chairman of the Board, effective immediately. Mr. Wold-Olsen will stand for re-election to the Board at the Company’s 2022 Annual Meeting in June. As part of a planned retirement, David Stack, a director since 2012, and Joe Zakrzewski, a director since 2010, will retire from the Board, effective at the close of the 2022 Annual Meeting. Mr. Wold-Olsen has been named Chair of the Remuneration Committee; Ms. Enright has been named Chair of the Audit Committee. Dr. Lars Ekman will remain a member of the Board. Ms. Enright brings more than 30 years of experience as a healthcare company executive and investor. She currently serves as Managing Partner at Prettybrook Partners, overseeing approximately 20 active investments in a variety of healthcare companies. Prior to her role at Prettybrook, Ms. Enright served as Chief Financial Officer of InfuSystem and as President of Lee Medical. Mr. Zulueta has more than three decades of experience in global strategic and leadership roles within large pharma, specifically with Eli Lilly and Company. At Eli Lilly, he held key senior positions including Vice President of Global Marketing, head of the Company’s Asia Region, and most recently as President of International responsible for all geographies outside the United States and Canada. Following the 2022 Annual Meeting - with the addition of Ms. Enright and Mr. Zulueta, and the planned retirements of Mr. Stack and Mr. Zakrzewski - the Amarin Board will comprise eight directors, seven of whom are independent.

Neutral

Amarin Corporation plc Presents at H.C. Wainwright Global Investment Conference 2022, May-25-2022 12:00 PM

2022-05-12 12:00:00

Amarin Corporation plc Presents at H.C. Wainwright Global Investment Conference 2022, May-25-2022 12:00 PM. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States. Speakers: Karim Mikhail, President, CEO & Director.

Neutral

Amarin Corporation plc Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 01:00 PM

2022-05-12 12:00:00

Amarin Corporation plc Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 01:00 PM. Venue: Marriott Marquis, New York City, New York, United States. Speakers: Karim Mikhail, President, CEO & Director.

Neutral

Amarin Corporation plc Suspends Revenue Guidance for the Full Year 2022

2022-05-04 11:00:00

Amarin Corporation plc suspended revenue guidance for the full year 2022. Given the ongoing global impact of COVID-19, as well as the uncertainty resulting from the impact of generic IPE availability in the U.S. and challenges for most drugs seeking market access in Europe, the company will continue to suspend 2022 revenue guidance; however, the company will continue to evaluate its ability to provide greater financial outlook insight as the year progresses.

Positive

Amarin Corporation plc Announces Results from Icosapent Ethyl on Risk of Major Cardiovascular Events

2022-05-03 12:00:00

Amarin Corporation plc announced the publication in the Journal of the American College of Cardiology (JACC) of a new REDUCE-IT® data analysis further strengthening evidence of the benefits of icosapent ethyl in adult patients most at risk of suffering from a potentially fatal or non-fatal cardiovascular (CV) event. This new sub-analysis was led by Deepak L. Bhatt, M.D., M.P.H., Brigham and Women’s Hospital, Harvard Medical School, Boston, MA. The patients identified in the new REDUCE-IT sub-analysis had experienced a prior myocardial infarction (MI), commonly called a heart attack, and as previously demonstrated, are therefore at much higher risk of another serious CV event without further intervention.(1) Research has shown that people who have had a heart attack are up to 50% more likely to have another CV event or heart procedure within only one year. The REDUCE-IT Prior MI sub-analysis studied 3,693 patients (45.2% of initial REDUCE-IT study population) who had a prior MI within a median of 4.8 years before randomization. Baseline characteristics were similar among patients randomized to icosapent ethyl versus placebo. Icosapent ethyl significantly reduced the primary composite endpoint (first occurrence of CV death, non-fatal MI, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina) by 26% (HR 0.74, 95% CI 0.65-0.85, P=0.00001), equating to an absolute risk reduction of 5.9%. Total events (first and subsequent events) were significantly reduced by 35% (RR 0.65, 95% CI 0.56-0.77, P=0.0000001) in patients with prior MI who are at high risk of another major event. Icosapent ethyl also led to a 29% reduction in the key secondary composite endpoint of CV death, non-fatal MI, or non-fatal stroke (equating to an absolute risk reduction of 4.7% (HR 0.71, 95% CI 0.61-0.84, P=0.00006)). Rates of sudden cardiac death and cardiac arrest were also significantly reduced, showing 40% relative risk reduction (P=0.02) and 56% relative risk reduction (P=0.02), respectively. The safety of icosapent ethyl among patients with prior MI was consistent with the main study findings in the entire population, with increased rates of atrial fibrillation and of minor bleeding, though no significant increase in major bleeding. These data included both prespecified and post hoc analyses. It Is important to note that the exploratory nature limited the post hoc analysis. REDUCE-IT was not powered for subgroup analyses and all P-values should be considered hypothesis generating. The landmark REDUCE-IT cardiovascular outcomes study, published in New England Journal of Medicine (NEJM) in 2019, enrolled 8,179 patients for a median of 4.9 years, who were required to be treated with statins and other standard of care therapies. All patients had controlled low-density lipoprotein cholesterol (LDL-C), elevated triglyceride levels, and either established CVD or diabetes with other cardiovascular risk factors.

Neutral

Amarin Corporation plc to Report Q1, 2022 Results on May 04, 2022

2022-04-19 11:30:00

Amarin Corporation plc announced that they will report Q1, 2022 results at 8:00 AM, Eastern Daylight on May 04, 2022

Neutral

Amarin Corporation plc, Q1 2022 Earnings Call, May 04, 2022

2022-04-19 11:30:00

Amarin Corporation plc, Q1 2022 Earnings Call, May 04, 2022

Neutral

Amarin Corporation plc Presents at American College of Cardiology Annual Scientific Session & Expo, Apr-02-2022

2022-03-21 12:30:00

Amarin Corporation plc Presents at American College of Cardiology Annual Scientific Session & Expo, Apr-02-2022 . Venue: Washington, District Of Columbia, United States.

Neutral

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022

2022-02-28 18:21:00

H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

American College of Cardiology, Inc., American College of Cardiology Annual Scientific Session & Expo, Apr 01, 2022 through Apr 04, 2022

2022-01-26 12:00:00

American College of Cardiology, Inc., American College of Cardiology Annual Scientific Session & Expo, Apr 01, 2022 through Apr 04, 2022. Venue: Washington, District Of Columbia, United States.

Negative

Levi & Korsinsky, LLP Announces Commencement of Securities Class Action Lawsuit Against Amarin Corporation plc

2021-11-24 20:50:00

Levi & Korsinsky, LLP announced that all persons or entities who purchased or otherwise acquired securities of Amarin Corporation Plc between December 5, 2018 and June 21, 2021. They are notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. According to the filed complaint: (i) there was an increasingly high risk that certain of Amarin's patents would be invalidated; (ii) once the District Court invalidated certain of Amarin's patents, there was little to no chance of reversing that ruling; (iii) the Company's litigation was preventing it from effectuating a successful takeover; (iv) Defendants were downplaying the true threat the ongoing abbreviated new drug application litigation posed to the company's business and future prospects; and (v) as a result, the company's public statements were materially false and misleading at all relevant times. If purchased Amarin securities between December 5, 2018 and June 21, 2021, may be entitled to compensation without payment of any out-of-pocket costs or fees.

Neutral

Amarin Corporation plc Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021

2021-11-22 15:06:00

Amarin Corporation plc Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.

Positive

Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid Presented at the American Heart Association Scientific Sessions 2021

2021-11-16 12:00:00

Amarin Corporation plc reported an overview of new data relating to VASCEPA®/VAZKEPA (icosapent ethyl) presented at the American Heart Association Scientific Sessions 2021, which took place virtually from November 13-15, 2021. Rapid Fire Oral Session Presentation: “Benefits of Icosapent Ethyl in Patients with Prior Peripheral Artery Disease: REDUCE-IT PAD,”– presented on behalf of all authors by Deepak L. Bhatt, M.D., M.P.H., Brigham and Women’s Hospital. Highlights: The investigators concluded that, “Icosapent ethyl 4 g/day significantly reduced total (first and subsequent) primary endpoints by 32%, and trended toward a 22% reduction in first events, in patients with PAD. Icosapent ethyl provides substantial cardiovascular risk reduction in the high-risk REDUCE-IT population, with consistent benefits in patients with a history of PAD. Safety was generally consistent with the overall study. Overall tolerability and adverse events were generally similar between icosapent ethyl and placebo in patients with prior PAD. More atrial fibrillation/flutter occurred with icosapent ethyl versus placebo in patients with prior PAD (5.2% versus 2.6%, respectively; P=0.07). No differences in bleeding were observed between icosapent ethyl and placebo in patients with prior PAD, likely due to the sample size.” e-Poster Presentation: Eicosapentaenoic Acid (EPA) Restores Pulmonary Endothelial Nitric Oxide Bioavailability Following Exposure to Urban Air Pollution Small Particles”– presented on behalf of all authors by R. Preston Mason, Ph.D., Brigham and Women’s Hospital. Highlights: This study examined the effects of EPA on pulmonary endothelial cell (PEC) function and inflammatory state when challenged with air pollution particulate matter isolated from an urban environment. In this study, primary PECs were pre-treated with EPA (40 µM) for two hours in 2% FBS-containing medium and then challenged with urban particulate matter (50 µg/mL) for two hours. After two hours, media was washed out and HBSS buffer was added. Cells were then stimulated with a calcium ionophore and concurrent measurements of nitric oxide and ONOO- were performed using tandem electrochemical nanosensors. In parallel with the endothelial function analysis, soluble intracellular adhesion molecule-1 (sICAM-1) was detected. The study authors concluded that, “EPA significantly improved pulmonary endothelial cell function under conditions of inflammation caused by air pollution particles, including reductions in nitroxidative stress and the soluble adhesion molecule ICAM-1. These effects of EPA in pulmonary tissue challenged with air particulate matter indicate a novel potential benefit for further exploration in people exposed to air pollution.” Late-Breaking Science Presentation: “Icosapent Ethyl Versus Placebo In Outpatients With COVID-19: The Main Results Of PREPARE-IT 2” – presented on behalf of all authors and the PREPARE-IT 2 Trial Investigators by Rafael Diaz, M.D., Estudios Cardiologicos Latinoamerica (ECLA), Rosario, Argentina. Highlights: These data represent the first presentation of the topline results from the PREPARE-IT 2 study, which was an investigator-initiated trial (IIT) to evaluate the efficacy of icosapent ethyl (IPE) to reduce hospitalizations or death in approximately 2000 patients in Argentina with a positive diagnosis for the COVID-19 virus. In this study, subjects were randomized 1:1 to receive IPE or placebo and received a loading dose of 8g per day of IPE for the first three days followed by 4g per day of IPE thereafter from days 4-28. The primary endpoint is COVID-19 related hospitalizations or death assessed through day 28. While the results of the PREPARE-IT 2 study in Argentina did not meet the primary and/or other endpoints studied, the company believe it is valuable for Amarin to support pilot IITs of this nature to determine the safety and potential efficacy of VASCEPA/VAZKEPA in a diverse group of at-risk populations. Importantly, the study supports the safety and tolerability of VASCEPA/VAZKEPA at varying doses. PREPARE-IT 1 and 2 are part of a series of IITs evaluating VASCEPA/VAZKEPA’s potential benefit in preventing and/or treating COVID-19. Amarin continues to support MITIGATE, another IIT study of IPE’s potential efficacy in the prevention of COVID-19. The results of this study have no relationship to or bearing on any approved indications for VASCEPA/VAZKEPA.

Neutral

Amarin Corporation plc Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-16-2021 08:40 AM

2021-11-11 12:00:00

Amarin Corporation plc Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-16-2021 08:40 AM. Venue: London, United Kingdom. Speakers: Karim Mikhail, President, CEO & Director, Michael W. Kalb, CFO, Senior VP & Assistant Secretary.

Neutral

Amarin Corporation plc Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021

2021-11-11 12:00:00

Amarin Corporation plc Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 . Speakers: Karim Mikhail, President, CEO & Director, Michael W. Kalb, CFO, Senior VP & Assistant Secretary.

Positive

Amarin Corporation plc Announces Latest Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) to Be Presented at American Heart Association Scientific Sessions 2021

2021-11-08 12:00:00

Amarin Corporation plc announced that new data that add to the growing body of knowledge on VASCEPA®/VAZKEPA (icosapent ethyl), including in patients at risk for major adverse cardiovascular events, will be presented at the American Heart Association (AHA) Scientific Sessions 2021 taking place virtually from November 13 – November 15, 2021. These new findings will be presented in Rapid Fire Oral Session and Late-Breaking Science presentations and an e-poster presentation from a variety of international academic collaborators based on research or analyses supported by Amarin. In addition to the clinical presentations outlined below, Amarin will be sponsoring a fully interactive virtual exhibit booth that will feature educational and promotional information on the cardiovascular risk reduction benefits of VASCEPA/VAZKEPA. Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From its foundation in scientific research to its focus on clinical trials, and now is commercial expansion, the company evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. The company committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk. Cardiovascular disease is the number one cause of death in the world. In the United States alone, cardiovascular disease results in 859,000 deaths per year.i And the number of deaths in the United States attributed to cardiovascular disease continues to rise. In addition, in the United States there are 605,000 new and 200,000 recurrent heart attacks per year (approximately 1 every 40 seconds). Stroke rates are 795,000 per year (approximately 1 every 40 seconds), accounting for 1 of every 19 U.S. deaths. In aggregate, in the United States alone, there are more than 2.4 million major adverse cardiovascular events per year from cardiovascular disease or, on average, 1 every 13 seconds. Controlling bad cholesterol, also known as LDL-C, is one way to reduce a patient’s risk for cardiovascular events, such as heart attack, stroke or death. However, even with the achievement of target LDL-C levels, millions of patients still have significant and persistent risk of cardiovascular events, especially those patients with elevated triglycerides. Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35%. Significant cardiovascular risk remains after statin therapy. People with elevated triglycerides have 35% more cardiovascular events compared to people with normal (in range) triglycerides taking statins. REDUCE-IT was a global cardiovascular outcomes study designed to evaluate the effect of VASCEPA in adult patients with LDL-C controlled to between 41-100 mg/dL (median baseline 75 mg/dL) by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides between 135-499 mg/dL (median baseline 216 mg/dL) and either established cardiovascular disease (secondary prevention cohort) or diabetes mellitus and at least one other cardiovascular risk factor (primary prevention cohort). REDUCE-IT, conducted over seven years and completed in 2018, followed 8,179 patients at over 400 clinical sites in 11 countries with the largest number of sites located within the United States. REDUCE-IT was conducted based on a special protocol assessment agreement with FDA. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology. The primary results of REDUCE-IT were published in The New England Journal of Medicine in November 2018. The total events results of REDUCE-IT were published in the Journal of the American College of Cardiology in March 2019. VASCEPA (icosapent ethyl) capsules are the first-and-only prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first and only drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk after statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (=500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed over ten million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, VASCEPA is approved and sold in Canada, Lebanon and the United Arab Emirates. In Europe, in March 2021 marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA.

Neutral

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021

2021-10-25 10:00:00

Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.

Negative

The Schall Law Firm and Roche Freedman LLP Files Securities Fraud Lawsuit Against Amarin Corporation, plc

2021-10-24 13:00:00

The Schall Law Firm and Roche Freedman LLP announced that they have filed a class action lawsuit in the United States District Court for the District of New Jersey, captioned Dang v. Amarin Corporation PLC, et. al., (Case No. 21-cv-19212), on behalf of plaintiff Vincent Dang and a class consisting of investors who purchased or otherwise acquired Amarin Corporation, plc (“Amarin” or “the Company”) securities between December 5, 2018, and June 21, 2021, inclusive (the ''Class Period''). Plaintiff seeks to recover compensable damages caused by Defendants' violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose material adverse facts about Amarin’s business and patent portfolio. Specifically, Defendants made false and misleading statements and/or failed to disclose that: (i) there was an increasingly high risk that certain of Amarin’s patents would be invalidated; (ii) once certain of Amarin’s patents were invalidated by the United States District Court for the District of Nevada, there was little to no chance of reversing that ruling; (iii) the Company’s litigation was preventing it from effectuating a successful takeover; (iv) Defendants were downplaying the true threat the ongoing Abbreviated New Drug Application (“ANDA”) litigation posed to the Company’s business and future prospects; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times. The truth about the strength of Amarin’s patent portfolio was partially revealed on March 30, 2020, when the Company announced that the United States District Court for the District of Nevada had “rul[ed] in favor of the generic companies in the company’s patent litigation against two filers of . ANDAs . for Amarin’s VASCEPA® (icosapent ethyl) capsule franchise.” On this news, the Company’s share price plummeted over 70.5% on heavy trading volume. On September 2, 2020, as the Court of Appeals for the Federal Circuit heard oral arguments for Amarin’s patent litigation, and the next day, affirmed the District Court’s ruling, the Company’s share price fell over 34.5% on heavy trading volume. Then, on April 12, 2021, Amarin announced the retirement of Defendant John F. Thero, the Company’s President and CEO. On this news, the Company’s share price fell over 14.3% to close at $5.08 on April 13, 2021, on heavy trading volume.

Neutral

Amarin Corporation plc, Q3 2021 Earnings Call, Nov 03, 2021

2021-10-20 11:05:00

Amarin Corporation plc, Q3 2021 Earnings Call, Nov 03, 2021

Neutral

Amarin Corporation plc to Report Q3, 2021 Results on Nov 03, 2021

2021-10-20 11:05:00

Amarin Corporation plc announced that they will report Q3, 2021 results on Nov 03, 2021

Positive

Amarin Outlines New Go-To-Market Strategy to Accelerate Vascepa® (Icosapent Ethyl) Growth in U.S

2021-09-27 12:31:00

Amarin Corporation plc outlined its new Go-to-Market strategy to accelerate growth of VASCEPA® (icosapent ethyl) in the United States, which focuses on expanding healthcare professional engagement through a new omnichannel platform, enhancing managed care access and optimizing VASCEPA prescriptions for cardiovascular (CV) risk reduction. Key Strategic Priorities: Enhancing Managed Care Access: Amarin will continue working with payers to enhance its strong managed care position and further remove barriers to VASCEPA prescriptions to ensure that patients in need of CV risk reduction receive proper therapy. Importantly, several large Commercial and Medicare Part D payers currently cover VASCEPA as the exclusive icosapent ethyl (IPE) product due to its cost-effectiveness. Optimizing VASCEPA Prescriptions for CV Risk Reduction: Today, branded VASCEPA remains the only available U.S. Food and Drug Administration (FDA) approved IPE medication for CV risk reduction. To prevent improper generic substitution for this indication, Amarin is continuing to aggressively educate critical stakeholders in the prescribing continuum to ensure proper fulfillment at each step. Additionally, Amarin is evaluating various innovative solutions designed to better manage IPE prescriptions for CV risk reduction.

Positive

Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany

2021-09-13 11:00:00

Amarin Corporation plc announced the first European launch of VAZKEPA (icosapent ethyl) in Germany. VAZKEPA received marketing authorization from the European Commission in March 2021 and the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain in April 2021. VAZKEPA is indicated as a treatment to reduce the risk of cardiovascular events in statin-treated adult patients at high cardiovascular risk who have elevated triglycerides (= 150 mg/dL [= 1.7 mmol/L]) and either established cardiovascular disease or diabetes and at least one additional cardiovascular risk factor. The European launch of VAZKEPA, beginning in Germany, is supported by more than a decade of evidence-based cardiovascular clinical outcomes research including the landmark REDUCE-IT® study, a groundbreaking study2 which established that VASCEPA®/VAZKEPA lowers the risk of a life-threatening heart attack or stroke by 25% when added to a statin in the targeted population. Importantly, VASCEPA/VAZKEPA has been included in the treatment guidelines for cardiovascular disease (CVD) prevention by the European Society of Cardiology, the European Association of Preventive Cardiology and the European Atherosclerosis Society, in addition to 17 other medical guidelines around the world. The launch of VAZKEPA in Germany featured a scientific conference in Berlin titled, “New therapeutic strategies for residual CV risk management,” which highlighted the scientific underpinnings and clinical benefits of VASCEPA/VAZKEPA in reducing cardiovascular risk. The symposium was led by eleven internationally renowned cardiovascular specialists, was attended by more than 200 healthcare professionals from Germany and was live streamed to many more physicians across the continent. The event has been archived and is available to thousands of physicians across Europe.

Neutral

Amarin Corporation plc Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 02:40 PM

2021-09-13 10:00:00

Amarin Corporation plc Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 02:40 PM. Venue: New York, United States.

Neutral

Amarin Corporation plc Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM

2021-09-13 10:00:00

Amarin Corporation plc Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States.

Positive

Amarin Reports Overview of Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at ESC Congress 2021, Organized by the European Society of Cardiology

2021-08-31 11:00:00

Amarin Corporation plc reported an overview of new data relating to VASCEPA®/VAZKEPA (icosapent ethyl) presented at ESC Congress 2021, organized by the European Society of Cardiology (ESC), taking place virtually from August 27 – August 30, 2021. ESC 2021 Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Amarin also reports that the ESC released their 2021 Guidelines on cardiovascular disease prevention in clinical practice, which includes icosapent ethyl (VAZKEPA) as a new recommendation to address high-risk cardiovascular patients with elevated triglycerides (135-499 mg/dL) despite statin treatment and lifestyle measures. The classification is a Level B recommendation, which reflects a relatively high weight of scientific evidence under ESC standards. This guideline was developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the ESC and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). With this new inclusion, VASCEPA/VAZKEPA is now included in 20 separate guidelines, scientific statements, or consensus statements. Highlights: These data represent the first presentation of the topline final results from the PREPARE-IT 1 study,which was an investigator-initiated trial (IIT) of approximately 2000 SARS CoV-2 negative, high-risk healthcareand other public workers in Argentina. In this study, subjects were randomized 1:1 to receive IPE or placeboand received a loading dose of 8 grams per day on days 1-3 and 4 grams per day on days 4-60. The primaryendpoint is the percentage of subjects positive for SARS-CoV-2 through day 60. While the results of the PREPARE-IT 1 study in Argentina did not meet the primary and/or other endpoints studied,we believe it is valuable for Amarin to support pilot investigator-initiated trials (IITs) of this nature todetermine the safety and potential efficacy of VASCEPA/VAZKEPA (icosapent ethyl) in a diverse group of at-riskpopulations. PREPARE-IT 1 is part of a series of IITs evaluating VASCEPA’s potential benefit in preventing and/or treatingCOVID-19. Amarin is looking forward to the results of the PREPARE-IT 2 and MITIGATE trials, as the totality ofthe data will advise the various clinical and regulatory pathways Amarin may explore for the potential use ofVASCEPA as an adjunctive treatment to reduce the risk of infection and/or as a treatment for COVID-19. The results of this study have no relationship to or bearing on the FDA-approved indication for VASCEPA toreduce CV risk when added to a statin.

Positive

Amarin Reports Data from Reduce-It® Showing Vascepa®/Vazkepa (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session At Esc Congress 2021, Organized by the European Society of Cardiology

2021-08-23 07:15:00

Amarin Corporation plc announced that data adding to the growing body of knowledge on VASCEPA®/VAZKEPA (icosapent ethyl) in patients with prior heart attack, known as myocardial infarction (MI), at risk for major adverse cardiovascular events were delivered in a Late Breaking Science Presentation at ESC Congress 2021, organized by the European Society of Cardiology (ESC), taking place virtually from August 27 – August 30, 2021. The presentation titled, “Reduction in Ischemic Events, Including Cardiovascular Mortality, with Icosapent Ethyl in Patients with Prior Myocardial Infarction: REDUCE-IT PRIOR MI,” was presented on behalf of all authors by Deepak L. Bhatt, M.D., M.P.H., Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital, Professor of Medicine at Harvard Medical School, and principal investigator of REDUCE-IT® and is available On-Demand beginning August 23, 2021 at 3:00 am ET (9:00 am CEST) through the completion of the Congress. The Late Breaking Science Presentation included both prespecified and post hoc analyses of patients who had prior MI from the REDUCE-IT study (prior to trial randomization) to determine if treatment with VASCEPA (icosapent ethyl) reduced further ischemic events in those subjects.

Positive

Amarin Corporation plc Announces Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2021

2021-08-16 11:00:00

Amarin Corporation plc announced that new data that add to the growing body of knowledge on VASCEPA®/VAZKEPA (icosapent ethyl) in patients at risk for major adverse cardiovascular events will be presented at ESC Congress 2021, organized by the European Society of Cardiology (ESC), being held virtually from August 27 – August 30, 2021. These and other new findings will be presented in two Late-Breaking Science presentations and five e-Poster presentations from a variety of international academic collaborators based on research or analyses supported by Amarin.

Neutral

Amarin Corporation plc to Report Q2, 2021 Results on Aug 05, 2021

2021-07-15 10:35:00

Amarin Corporation plc announced that they will report Q2, 2021 results on Aug 05, 2021

Neutral

Amarin Corporation plc, Q2 2021 Earnings Call, Aug 05, 2021

2021-07-15 10:35:00

Amarin Corporation plc, Q2 2021 Earnings Call, Aug 05, 2021

Fundamental Summary

Amarin's financial reports for Q1 showed some underwhelming results. Specifically, their growth, value, and income factors indicate an execution challenge when it comes to generating exciting and consistent growth. Typically, results like these translate into sustained negative momentum and strong downward pressure on stock price. Therefore, we assessed them with a rating of 52 and a UNDERPERFORM recommendation.

Amarin reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 142.04 million compared to USD 156.5 million a year ago. Net loss was USD 13.15 million compared to USD 6.79 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.02 a year ago. Diluted loss per share from continuing operations was USD 0.03 compared to USD 0.02 a year ago.For the nine months, revenue was USD 438.7 million compared to USD 446.81 million a year ago. Net loss was USD 6.97 million compared to USD 22.93 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.06 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to USD 0.06 a year ago.

Business Description

Amarin, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin in 1999. Amarin was incorporated in 1989 and is headquartered in Dublin, Ireland.

Sector Overview

Amarin is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Amarin's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 973.7 -8.8% 65
Liabilities 332.6 -17.1% 51
Price to Book 1.1 -44.1% 51
Cash & Equivalents 219.2 -0.1% 72
Equity 641.1 -3.9% 58
EBITDA 2.8 -90.5% 44
Total Revenues 535.6 -8.2% 95
Parameter Value Change Score
Return on Equity -3.5 -391.6% 82
Net Cashflow -71.8 -321.1% 52
Capital Expenditure 0.0 -100.0% 74
Asset Turnover 0.5 -4.9% 55
Free Cashflow -0.4 -120.0% 40

* All values are TTM

The below chart reflects Amarin's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Amarin's peer average final assessment score stands on 64.0, Amarin's score is 52.

  •  AMRN
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 0 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 1 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 2 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 3 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 4 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 5 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 6 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 7 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 8 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 9 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 10 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 11 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 12 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 13 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 14 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 15 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 16 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 17 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 18 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 19 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 20 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 22 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 23 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 24 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 26 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 27 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 28 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 30 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 31 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 32 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 33 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 34 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 35 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 36 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 37 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 39 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 40 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 41 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 42 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 43 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 44 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 46 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 47 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 48 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 50 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 54 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 55 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 57 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 58 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 59 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 60 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 61 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 62 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 65 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 66 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 69 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 70 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 73 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 74 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 75 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 76 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 77 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 80 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 81 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 82 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 83 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 84 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 85 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 92 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 93 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 94 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 95 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Amarin's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is strengthening. Historically, this is a negative setup in the near, medium, and long-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Amarin's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 52.

Bearish 52
Close Price 1.85
52W Low 1.13
52W High 5.84
5D MA 1.91
50D MA 1.92
200D MA 3.37
MACD 0.03
RSI 4.27
STOCH 51.72

Balance Sheet Analysis

Amarin's recently published balance sheet showed overall, underwhelming numbers. Both Liabilities and Book Value Factors were particularly concerning. Amarin's liabilities stood at 332.6 in the current filing, which represents a -17.1% change from the previous report. These liabilities metrics show that management has been unsuccessful in encouraging healthy growth while managing liabilities. Its liabilities movement component, therefore, received a grade of 51. Also, Amarin publishes concerning book value factor metrics in this report. price to book ratio (P/B) now sits at 1.1 and represents -44.1% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. They does not yet appear to be headed in the right direction to achieve strong book value metrics. Consequently, their book value factors movement received a grade of 51. However, one encouraging metric, Cash & Equivalents, stood out. Amarin did a great job related to cash and cash equivalents this period, which stood at 219.2, representing a -0.1% change from the previous filing. This performance is significantly more impressive than its peers and competitors. It suggests that their stock price has room to grow to reflect its actual intrinsic value. Consequently, their cash and cash equivalents movement received a grade of 72. The company's balance sheet, Therefore, earned a score of 55.

Parameter Value Change Score
Assets 973.7 -8.8% 65
Liabilities 332.6 -17.1% 51
Price to Book 1.1 -44.1% 51
Cash & Equivalents 219.2 -0.1% 72
Equity 641.1 -3.9% 58
* All values are TTM

The below chart describes Amarin's performance as reflected on its balance sheet with respect to its peers. While Amarin received a balance sheet score of 55, the average of its peers stands on 64.0.

  •  AMRN
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 0 1
CureVac N.V. 2.6B 49 64 75 52 52 57 1 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 2 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 3 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 4 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 5 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 6 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 7 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 8 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 9 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 10 1
CareDx, Inc 1.2B 54 67 52 39 51 52 11 1
MannKind Corporation 957.2M 79 59 50 40 64 57 12 1
Merus N.V. 941.6M 59 68 50 83 81 70 13 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 14 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 15 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 16 1
Affimed N.V. 415.0M 56 66 63 56 47 54 17 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 18 1
AC Immune SA 299.8M 84 64 47 53 75 68 19 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 20 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 22 1
Amgen Inc. 130.1B 72 68 86 53 62 69 23 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 24 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 26 1
BioNTech SE 34.0B 75 69 64 97 73 75 27 1
Seagen Inc. 32.9B 59 68 55 43 66 61 28 1
Biogen Inc. 29.7B 57 72 92 50 76 76 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 30 1
Incyte Corporation 16.8B 71 72 95 82 79 83 31 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 32 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 33 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 34 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 35 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 36 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 37 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 38 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 39 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 40 1
Alkermes plc 5.0B 63 66 46 54 71 62 41 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 42 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 43 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 44 1
Natera, Inc. 3.6B 73 65 43 95 42 54 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 46 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 47 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 48 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 50 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 54 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 55 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 57 1
Vericel Corporation 1.1B 51 65 56 53 61 57 58 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 59 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 60 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 61 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 62 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 63 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 65 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 66 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 69 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 70 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 73 1
Geron Corporation 566.2M 69 72 37 59 62 60 74 1
Immatics N.V. 538.7M 56 70 84 95 73 76 75 1
Agenus Inc. 520.5M 73 62 37 55 60 54 76 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 77 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 80 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 81 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 82 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 83 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 84 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 85 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 92 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 93 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 94 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 95 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Amarin appears likely to maintain its strong income statement metrics and momentum going forward. Amarin reported highly encouraging numbers for its revenue efficiency. This characteristic can affect companies in the same industry and market capitalization by up to 13.1%. Their revenue efficiency, specifically in contrast to their industry peers', should support a positive movement in the company's stock price. As a result, its revenue efficiency earned a score of 95. Also, Amarin's reported return on equity (ROE) ratio was -3.5, representing a change of -391.6%. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. Therefore, its return factors component earned a score of 82. That said, one metric, EBITDA, stood out as strongly negative. Amarin's EBIDTA now sits at 2.8 and represents -90.5% change from the last reporting period. This metric might have a 24.4 percent impact on companies in the same industry and with the same market capitalization. The company's EBITDA metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Its EBITDA movement, therefore, received a grade of 44. As the companie's management is doing an excellent job managing the critical metrics, the income statement was given a score of 63.

Parameter Value Change Score
EBITDA 2.8 -90.5% 44
Total Revenues 535.6 -8.2% 95
Return on Equity -3.5 -391.6% 82
* All values are TTM

The below chart describes Amarin's performance as reflected on its income statement with respect to its peers. While Amarin received a income statement score of 63 , the average of its peers stands on 65.0.

  •  AMRN
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 0 1
CureVac N.V. 2.6B 45 83 71 74 1 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 2 1
Abgenix Inc. 2.1B 47 47 47 47 3 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 4 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 5 1
Xencor, Inc. 1.6B 42 94 52 79 6 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 7 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 8 1
Veracyte, Inc. 1.4B 45 63 57 55 9 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 10 1
CareDx, Inc 1.2B 61 44 82 50 11 1
MannKind Corporation 957.2M 95 48 56 61 12 1
Merus N.V. 941.6M 48 60 59 54 13 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 14 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 15 1
Radius Health, Inc. 499.8M 94 71 68 82 16 1
Affimed N.V. 415.0M 95 49 75 66 17 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 18 1
AC Immune SA 299.8M 83 61 65 70 19 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 20 1
Chimerix, Inc. 178.4M 99 50 62 65 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 22 1
Amgen Inc. 130.1B 74 75 64 78 23 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 24 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 26 1
BioNTech SE 34.0B 41 89 75 79 27 1
Seagen Inc. 32.9B 54 65 70 62 28 1
Biogen Inc. 29.7B 90 57 73 70 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 30 1
Incyte Corporation 16.8B 59 77 60 73 31 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 32 1
United Therapeutics Corporation 10.6B 57 91 54 82 33 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 34 1
Exact Sciences Corporation 7.2B 57 67 54 62 35 1
Exelixis, Inc. 6.7B 54 91 54 81 36 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 37 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 39 1
Ascendis Pharma A/S 5.2B 38 68 46 54 40 1
Alkermes plc 5.0B 69 55 81 62 41 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 42 1
Novavax, Inc. 4.0B 41 89 54 75 43 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 44 1
Natera, Inc. 3.6B 52 51 78 52 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 46 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 47 1
Insmed Incorporated 2.4B 51 58 73 57 48 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 50 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 54 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 55 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 56 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 57 1
Vericel Corporation 1.1B 76 44 82 56 58 1
IVERIC bio, Inc. 1.1B 84 58 79 70 59 1
FibroGen, Inc. 1.0B 48 74 63 67 60 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 61 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 62 1
ImmunoGen, Inc. 946.1M 40 73 71 64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 65 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 66 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 68 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 69 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 70 1
CTI BioPharma Corp. 603.6M 84 50 62 59 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
AnaptysBio, Inc. 586.3M 97 50 77 68 73 1
Geron Corporation 566.2M 89 67 73 78 74 1
Immatics N.V. 538.7M 37 93 53 77 75 1
Agenus Inc. 520.5M 57 83 45 74 76 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 77 1
Vaxart, Inc. 440.0M 99 51 72 68 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
MiMedx Group, Inc. 391.5M 87 43 83 59 80 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 81 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 82 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 83 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 84 1
Zymeworks Inc. 324.7M 58 53 77 56 85 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
Precigen, Inc. 299.1M 57 87 59 79 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
bluebird bio, Inc. 288.7M 99 91 61 96 92 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 93 1
MacroGenics, Inc. 184.6M 95 56 74 71 94 1
DermTech, Inc. 165.3M 49 48 78 52 95 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Results from Amarin's current financials were concerning, in two areas in particular: Free Cash flow and Net Cash Flow. Free cash flow numbers published by Amarin were -0.4, which was a -120.0% change from the previous filing. Companies in the same sector and market capitalization will usually be affected by up to 2.6 percent by this parameter. their free cash flow situation appears to be much weaker than their peers. Management needs to do a better job balancing cash flow, asset growth, and resources allocations in general. Disappointing results in free cash flow often lead to negative pressure in stock prices, so we rated their free cash flow with a score of 40. Also, Amarin's management was not successful in meaningfully improving their cash flow metrics. As of the current filing, they were reported as -71.8 and represented a -321.1% change from the previous period. As demonstrated by these concerning net cash flow metrics, their priorities seem to be headed in the wrong direction. Consequently, their net cash flow movement received a grade of 52. On the other hand, Capex, jumped out as looking rather positive. Amarin's management was effective in improving its CapEx, which now sits at 0.0 and represents -100.0% change from the previous report. The company appears to be headed in the right direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. Consequently, their CapEx movement received a grade of 74. The company's cash flow, Therefore, earned a score of 55.

Parameter Value Change Score
Net Cashflow -71.8 -321.1% 52
Capital Expenditure 0.0 -100.0% 74
Asset Turnover 0.5 -4.9% 55
Free Cashflow -0.4 -120.0% 40
* All values are TTM

The below chart describes Amarin's performance as reflected on its cash flow with respect to its peers. While Amarin received a cash flow score of 55, the average of its peers stands on 68.0.

  •  AMRN
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 0 1
CureVac N.V. 2.6B 87 80 90 70 90 1 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 2 1
Abgenix Inc. 2.1B 66 53 45 59 58 3 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 4 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 5 1
Xencor, Inc. 1.6B 96 95 70 95 98 6 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 7 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 8 1
Veracyte, Inc. 1.4B 90 95 46 46 82 9 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 10 1
CareDx, Inc 1.2B 98 84 40 50 86 11 1
MannKind Corporation 957.2M 77 56 43 37 66 12 1
Merus N.V. 941.6M 70 71 74 53 71 13 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 14 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 15 1
Radius Health, Inc. 499.8M 64 40 37 56 57 16 1
Affimed N.V. 415.0M 72 57 95 43 74 17 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 18 1
AC Immune SA 299.8M 66 77 79 63 68 19 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 20 1
Chimerix, Inc. 178.4M 80 84 95 47 83 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 22 1
Amgen Inc. 130.1B 80 74 67 74 81 23 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 24 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 26 1
BioNTech SE 34.0B 73 97 50 52 72 27 1
Seagen Inc. 32.9B 53 53 50 87 58 28 1
Biogen Inc. 29.7B 58 54 90 73 66 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 30 1
Incyte Corporation 16.8B 78 79 92 74 84 31 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 32 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 33 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 34 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 35 1
Exelixis, Inc. 6.7B 79 90 89 83 87 36 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 37 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 38 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 39 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 40 1
Alkermes plc 5.0B 89 95 76 80 92 41 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 42 1
Novavax, Inc. 4.0B 62 38 63 54 60 43 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 44 1
Natera, Inc. 3.6B 52 54 56 84 58 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 46 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 47 1
Insmed Incorporated 2.4B 79 80 61 89 82 48 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 50 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 54 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 55 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 56 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 57 1
Vericel Corporation 1.1B 64 46 59 73 65 58 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 59 1
FibroGen, Inc. 1.0B 86 74 48 87 84 60 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 61 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 62 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 63 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 65 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 66 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 68 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 69 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 70 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 73 1
Geron Corporation 566.2M 78 68 49 81 77 74 1
Immatics N.V. 538.7M 82 95 56 99 86 75 1
Agenus Inc. 520.5M 57 43 52 77 58 76 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 77 1
Vaxart, Inc. 440.0M 72 56 53 38 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 80 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 81 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 82 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 83 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 84 1
Zymeworks Inc. 324.7M 52 65 45 83 57 85 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
Precigen, Inc. 299.1M 82 75 37 85 74 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 92 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 93 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 94 1
DermTech, Inc. 165.3M 60 51 45 86 58 95 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.